Meeting
2023 ASCO Annual Meeting
Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).
Authors
Belen Sierra-Rodero
Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Belen Sierra-Rodero , Alberto Cruz Bermudez , Cristina Martinez-Toledo , Marta Molina-Alejandre , Aránzazu García-Grande , Virginia Calvo , Ernest Nadal , Rosario Garcia Campelo , Amelia Insa , Manuel Domine , Bartomeu Massuti , Alberto Garrido , Margarita Majem , Alex Martinez-Marti , Javier de Castro Carpeño , Delvys Rodriguez-Abreu , Manuel Cobo , Isidoro Barneto , Santiago Viteri , Mariano Provencio-Pulla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8551)
DOI
10.1200/JCO.2023.41.16_suppl.8551
Abstract #
8551
Poster Bd #
178
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma.
First Author: Adrienne Sallets
Poster
2016 Gastrointestinal Cancers Symposium
Prognostic impact of tumor-associated B-cells and plasma cells in esophageal and gastric adenocarcinoma.
First Author: Richard Fristedt
Poster
2024 ASCO Annual Meeting
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.
First Author: Yana Qi
Poster
2023 ASCO Annual Meeting
Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
First Author: Jianliang Yang